Latest MicroRNA Stories
LA JOLLA, Calif., Feb. 20, 2014 /PRNewswire/ -- Regulus Therapeutics Inc.
-RG-012 is an anti-miR Targeting microRNA-21 for the Treatment of Alport Syndrome, a Life-Threatening, Genetic Kidney Disease with No Approved Therapy- LA JOLLA, Calif., Feb.
-Martin Beaulieu, Ph.D. Brings Extensive Diagnostic Assay Development Experience- LA JOLLA, Calif., Feb.
In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence
An international team of researchers, led by scientists from the University of California, San Diego School of Medicine and Indiana University, have identified a protein that broadly regulates how genetic information transcribed from DNA to messenger RNA (mRNA) is processed and ultimately translated into the myriad of proteins necessary for life.
-Regulus to Develop microRNA-21 for Alport Syndrome, a Life-Threatening Orphan Kidney Disease, and microRNA-21 in Oncology, to Human Proof-of-Concept- LA JOLLA, Calif.,
LA JOLLA, Calif., Feb. 3, 2014 /PRNewswire/ -- Regulus Therapeutics Inc.
Researchers have identified diagnostic microRNA panels in whole blood that had the ability to distinguish, to some degree, patients with and without pancreatic cancer.
GENSIGNIA plans to introduce minimally invasive diagnostic test which is urgently needed to improve the diagnostic performance of high resolution imaging for lung cancer detection
-Regulus microMarkers(TM) Designed to Support Regulus' Therapeutic Pipeline, its Collaborators and Strategic Partners- LA JOLLA, Calif., Jan.
- The abrogation of a law by a higher authority; annulment.